Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
作者： Nobuhisa Akamatsu , Yasuhiko Sugawara , Norihiro Kokudo
DOI: 10.1586/14787210.2015.1091724
关键词:
摘要: Asunaprevir, a second-generation NS3 protease inhibitor of hepatitis C virus (HCV), exhibits strong antiviral activity against HCV genotypes 1 and 4, but relatively weak 2 3. For chronic infection, asunaprevir with daclatasvir as an interferon-free dual treatment achieves sustained virologic response nearly 90% in genotype 1b, triple regimen beclabuvir >90%. Asunaprevir can be safely effectively administered to liver transplant recipients recurrent HCV. The major drawback is its low threshold resistance, which overcome by combining it other direct-acting antivirals. Further studies combination antivirals for the patients or 4 renal impairment end-stage disease under hemodialysis, HIV-coinfection and/or kidney are warranted.
sci-hub.se 参考文章(71)
Jean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, Dominique Larrey, Claudia T Martorell, Vinod K Rustgi, David W Morris, Ziad Younes, Michael W Fried, Marc Bourlière, Christophe Hézode, K Rajender Reddy, Omar Massoud, Gary A Abrams, Vlad Ratziu, Bing He, Timothy Eley, Alaa Ahmad, David Cohen, Robert Hindes, Fiona McPhee, Bridget Reilly, Patricia Mendez, Eric Hughes, Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Therapy. ,vol. 18, pp. 885- 893 ,(2013) , 10.3851/IMP2660
Fred Poordad, William Sievert, Lindsay Mollison, Michael Bennett, Edmund Tse, Norbert Bräu, James Levin, Thomas Sepe, Samuel S Lee, Peter Angus, Brian Conway, Stanislas Pol, Nathalie Boyer, Jean-Pierre Bronowicki, Ira Jacobson, Andrew J Muir, K Rajender Reddy, Edward Tam, Grisell Ortiz-Lasanta, Victor de Lédinghen, Mark Sulkowski, Navdeep Boparai, Fiona McPhee, Eric Hughes, E Scott Swenson, Philip D Yin, UNITY-1 Study Group, Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection JAMA. ,vol. 313, pp. 1728- 1735 ,(2015) , 10.1001/JAMA.2015.3860
Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes, Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection Hepatology. ,vol. 59, pp. 2083- 2091 ,(2014) , 10.1002/HEP.27113
Andrew J. Muir, Fred Poordad, Jacob Lalezari, Gregory Everson, Gregory J. Dore, Robert Herring, Aasim Sheikh, Paul Kwo, Christophe Hézode, Paul J. Pockros, Albert Tran, Joseph Yozviak, Nancy Reau, Alnoor Ramji, Katherine Stuart, Alexander J. Thompson, John Vierling, Bradley Freilich, James Cooper, Wayne Ghesquiere, Rong Yang, Fiona McPhee, Eric A. Hughes, E. Scott Swenson, Philip D. Yin, Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis JAMA. ,vol. 313, pp. 1736- 1744 ,(2015) , 10.1001/JAMA.2015.3868
Satoshi Yoshimi, Michio Imamura, Eisuke Murakami, Nobuhiko Hiraga, Masataka Tsuge, Yoshiiku Kawakami, Hiroshi Aikata, Hiromi Abe, C. Nelson Hayes, Tamito Sasaki, Hidenori Ochi, Kazuaki Chayama, Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. Journal of Medical Virology. ,vol. 87, pp. 1913- 1920 ,(2015) , 10.1002/JMV.24255
Yoshihide Ueda, Toshimi Kaido, Etsuro Hatano, Shigeru Ohtsuru, Shinji Uemoto, Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C Hepatology Research. ,vol. 45, pp. 1360- 1362 ,(2015) , 10.1111/HEPR.12509
Michael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, Norah A. Terrault, Jacqueline G. O'Leary, Hugo E. Vargas, Alexander Kuo, Eugene Schiff, Mark S. Sulkowski, Richard Gilroy, Kymberly D. Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M. Korenblat, Andrew J. Muir, Lewis Teperman, Robert J. Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Nezam Afdhal, Princy Kumar, Eugene Schiff, Nezam Afdhal, Robert S. Brown, Michael Fried, Kris Kowdley, Norah Terrault, Michael Charlton, Paul Kwo, Steve Flamm, John Lake, Greg Everson, Mark Sulkowski, Michael Curry, Rajender Reddy, Lewis Teperman, Hugo Vargas, Surakit Pungpapong, Andrew Muir, Atif Zaman, Kimberly Brown, Charles Landis, Alexander Kuo, Robert Fontana, Jacqueline O'Leary, Richard Gilroy, Obaid Shaikh, Kevin Korenblat, Richard Stravitz, Kymberly Watt, Narayanan Menon, James Bredfeldt, Carlos Romero-Marrero, Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease Gastroenterology. ,vol. 149, pp. 649- 659 ,(2015) , 10.1053/J.GASTRO.2015.05.010
Fiona McPhee, Yoshiyuki Suzuki, Joji Toyota, Yoshiyasu Karino, Kasuaki Chayama, Yoshiiku Kawakami, Min Lung Yu, Sang Hoon Ahn, Hiroki Ishikawa, Rafia Bhore, Nannan Zhou, Dennis Hernandez, Patricia Mendez, Hiromitsu Kumada, High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms Advances in Therapy. ,vol. 32, pp. 637- 649 ,(2015) , 10.1007/S12325-015-0221-5
Timothy Eley, Tushar Garimella, Wenying Li, Richard J. Bertz, Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions Clinical Pharmacokinetics. ,vol. 54, pp. 1205- 1222 ,(2015) , 10.1007/S40262-015-0299-6
Anna S. Lok, David F. Gardiner, Christophe Hézode, Eric J. Lawitz, Marc Bourlière, Gregory T. Everson, Patrick Marcellin, Maribel Rodriguez-Torres, Stanislas Pol, Lawrence Serfaty, Timothy Eley, Shu-Pang Huang, Jianling Li, Megan Wind-Rotolo, Fei Yu, Fiona McPhee, Dennis M. Grasela, Claudio Pasquinelli, Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders Journal of Hepatology. ,vol. 60, pp. 490- 499 ,(2014) , 10.1016/J.JHEP.2013.10.019